user

Efficacy and safety of Herceptin in women with Her2-positive (HER2+) metastatic breast cancer (MBC) who have progressed on a prior herceptin-containing regimen.

被引：0
|
作者：
Gelmon, K [1 ]
Mackey, J [1 ]
Verma, S [1 ]
Gertler, SZ [1 ]
Bangermann, N [1 ]
Klimo, P [1 ]
Schneeweiss, A [1 ]
Bremer, K [1 ]
Soulieres, D [1 ]
Tonkin, K [1 ]
Bell, R [1 ]
Heinrich, B [1 ]
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
440
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [41] An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.
    Ponde, Noam Falbel
    Ameye, Lieveke
    Lambertini, Matteo
    Paesmans, Marianne
    De Azambuja, Evandro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Herceptin (R) is active as a single agent in women with metastatic breast cancer overexpressing HER2
    Cobleigh, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S316 - S316
  • [43] Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?
    Haji, Farnaz
    Hurvitz, Sara A.
    CLINICAL BREAST CANCER, 2021, 21 (06) : 526 - 531
  • [44] Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study
    Yin, Sha
    Chi, Yajing
    Du, Yangyang
    Wang, Jingfen
    Shan, Changping
    Yi, Weiwei
    Shang, Mao
    Man, Xiaochu
    Tan, Qiaorui
    Li, Huihui
    CANCER MEDICINE, 2023, 12 (03): : 2333 - 2344
  • [45] Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who progressed on previous anti-HER2 ADCs
    Hamilton, Erika
    Petit, Thierry
    Pistilli, Barbara
    Goncalves, Anthony
    Ferreira, Ana Alexandra
    Dalenc, Florence
    Cardoso, Fatima
    Mita, Monica M.
    Manso, Luis
    Karim, Syed M.
    Bidard, Francois-Clement
    Aftimos, Philippe
    Escrivaa-de-Romanii, Santiago
    Afonso, Noemia
    Wasserman, Ernesto
    Bol, Kees
    Stalbovskaya, Viktoriya
    Vliet, Anastasia
    Murat, Anastasia
    Bekradda, Mohamed
    Bachelot, Thomas
    CANCER RESEARCH, 2022, 82 (04)
  • [46] PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer
    Metcalfe, Scott
    Evans, Jackie
    Priest, Ginny
    NEW ZEALAND MEDICAL JOURNAL, 2007, 120 (1256) : 80 - 99
  • [47] Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer
    Xiaoying Chen
    Cheryl Li
    Reginald Ewesuedo
    Donghua Yin
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 83 - 92
  • [48] Clinical factors associated with overall survival (OS) for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) treated with HER2-targeting systemic therapy (HER2Tx)
    Gullo, G.
    Walsh, N.
    Zacchia, A.
    Hammond, L.
    Fennelly, D.
    Walshe, J.
    O'Mahony, K.
    Maltese, M.
    Crown, J.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S44 - S44
  • [49] Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer
    Chen, Xiaoying
    Li, Cheryl
    Ewesuedo, Reginald
    Yin, Donghua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 83 - 92
  • [50] Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer
    Bonny Parkinson
    Rosalie Viney
    Marion Haas
    Stephen Goodall
    Preeyaporn Srasuebkul
    Sallie-Anne Pearson
    PharmacoEconomics, 2016, 34 : 1039 - 1050
12345